Anzeige
❌
Mehr »
Montag, 16.11.2026 - Börsentäglich über 12.000 News
GBC-Kursziel 2,00 CAD bis Juni 2027, Kurs 0,67 CAD: Verdreifachung drin?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
AP

WKN: A1W15D | ISIN: US00182C1036 | Ticker: BSFA
Frankfurt
16.11.26 | 09:55
63,50 Euro
0,00 % 0,00
1-Jahres-Chart
ANI PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
ANI PHARMACEUTICALS INC 5-Tage-Chart
RealtimeGeldBriefZeit
64,5065,5015:35
64,5065,5015:35

Aktuelle News zur ANI PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
13:00ANI PHARMACEUTICALS INC - 8-K, Current Report-
09.11.ANI Pharmaceuticals: Egetis Therapeutics Acquisition Valued At $560 Million To Expand Rare Disease Business3
05.11.ANI Pharma to buy Swedish biotech Egetis for $560M4
05.11.ANI PHARMACEUTICALS INC - 10-Q, Quarterly Report-
05.11.ANI PHARMACEUTICALS INC - 8-K, Current Report-
05.11.ANI Pharmaceuticals, Inc.: ANI Pharmaceuticals Announces Offer to Acquire Egetis Therapeutics, Expanding the Scope and Scale of Its Rare Disease Business3
05.11.Egetis Therapeutics AB: Statement by the Board of Directors of Egetis Therapeutics in relation to the public cash offer from ANI Pharmaceuticals197The Board of Directors of Egetis unanimously recommends that the shareholders of Egetis and the holder of the Convertible and the Warrants accept the public offer from ANI, based on the assessment outlined...
► Artikel lesen
05.11.ANI PHARMACEUTICALS INC: ANI Pharmaceuticals announces a recommended cash offer to the shareholders and to the holder of the Convertible and the Warrants of Egetis Therapeutics1
ANI PHARMACEUTICALS Aktie jetzt für 0€ handeln
04.11.ANI Pharmaceuticals Q3 2026 Earnings Preview1
23.10.ANI Pharmaceuticals, Inc.: ANI Pharmaceuticals to Discuss Third Quarter 2026 Financial Results on November 5, 2026 at 8:00 a.m. ET3
19.10.ANI Pharmaceuticals bringt Duloxetin-Generikum auf den Markt1
19.10.ANI Pharmaceuticals launches generic duloxetine capsules1
19.10.ANI Pharmaceuticals, Inc.: ANI Pharmaceuticals Announces the Launch of Duloxetine Delayed-Release Capsules1
12.10.ANI Pharma reports positive phase 4 data for Iluvien in non-infectious uveitis2
12.10.ANI Pharmaceuticals, Inc.: ANI Pharmaceuticals Announces Positive Phase 4 Open-Label, Single-Arm SYNCHRONICITY Clinical Trial Results Presented as Late Breaking Oral Presentation at the American Academy of Ophthalmology 2026 Annual Meeting2
30.09.ANI Pharmaceuticals, Inc.: ANI Pharmaceuticals Announces New Fluocinolone Acetonide Intravitreal Implant Data to be Presented at the American Academy of Ophthalmology 2026 Annual Meeting1
23.09.Ocular Therapeutix and ANI Pharmaceuticals Stocks Trade Down, What You Need To Know17
23.09.Oppenheimer initiates ANI Pharmaceuticals stock with Perform rating1
23.09.ANI Pharmaceuticals gets FDA approval for generic everolimus1
23.09.ANI Pharmaceuticals, Inc.: ANI Pharmaceuticals Announces the FDA Approval of Everolimus Tablets for Oral Suspension345PRINCETON, N.J., Sept. 23, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that it received final approval from the U.S. Food and Drug Administration...
► Artikel lesen
1 2 3 Weiter >>
54 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1